Efficacy and safety of ultrasound‐guided radiofrequency ablation of hyperplastic parathyroid gland for secondary hyperparathyroidism associated with chronic kidney disease. Issue 3 (29th December 2016)

• Record Type: Journal Article
• Authors: Peng, Chengzhong; Zhang, Zhengxian; Liu, Jibin; Chen, Hongyu; Tu, Xiao; Hu, Rihong; Ni, Jun; Weng, Ning; Pang, Haisu; Xue, Zhengmei
• Is Part Of: Head & neck. Volume 39:Issue 3(2017)
• Page Start: 564
• Page End: 571
• Publication Date: 2016-12-29
• Subjects: hyperplastic parathyroid gland -- radiofrequency ablation -- secondary hyperparathyroidism -- chronic kidney disease -- intact parathyroid hormone; Head -- Diseases -- Periodicals; Neck -- Diseases -- Periodicals; Head -- Periodicals; Neck -- Periodicals; Face -- Periodicals; 617.51059
• DOI: 10.1002/hed.24657
• Languages: English
• ISSNs: 1043-3074

Abstract

Abstract: Background: The purpose of this study was to determine if ultrasound‐guided radiofrequency ablation (RFA) of hyperplastic parathyroid glands could be used to treat secondary hyperparathyroidism (HPT) in patients with chronic kidney disease. Methods: RFA of the hyperplastic parathyroid glands was performed in 34 patients with secondary HPT. Intact parathyroid hormone (iPTH), calcium, and phosphorus were measured. The outcome was based on the ablation extent (ie, 4, 3, and 1–2 glands). Results: The iPTH, calcium, and phosphorus levels decreased in all groups after RFA. One year after ablation, these parameters remained significantly lower in the 4‐gland ablation group compared with the 3‐gland and 1 to 2‐gland groups. The same tendency was observed for the symptom score. The iPTH levels of <272 pg/mL on the day after ablation was the best predictor for maintaining parathyroid hormone (PTH) levels in a reasonable range 1 year after ablation. Conclusions: RFA of hyperplastic parathyroid glands for treating secondary HPT is feasible in selected patients. © 2016 Wiley Periodicals, Inc. Head Neck 39: 564–571, 2017